Application of iPS cell-derived macrophages to cancer therapy

We established a method to produce a large quantity of myeloid cells from human inducible pluripotent stem cells (iPSCs). When injected intraperitoneally into mice carrying established peritoneal tumors, iPSC-derived myeloid cells (iPS-MCs) efficiently accumulated within neoplastic lesions. The intr...

Descripción completa

Detalles Bibliográficos
Autores principales: Senju, Satoru, Koba, Chihiro, Haruta, Miwa, Matsunaga, Yusuke, Matsumura, Keiko, Haga, Eriko, Sasaki, Yuko, Ikeda, Tokunori, Takamatsu, Koutaro, Nishimura, Yasuharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2014
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008454/
https://www.ncbi.nlm.nih.gov/pubmed/24800175
http://dx.doi.org/10.4161/onci.27927
Descripción
Sumario:We established a method to produce a large quantity of myeloid cells from human inducible pluripotent stem cells (iPSCs). When injected intraperitoneally into mice carrying established peritoneal tumors, iPSC-derived myeloid cells (iPS-MCs) efficiently accumulated within neoplastic lesions. The intraperitoneal injection of iPS-MCs expressing interferon β significantly inhibited the growth of human gastric and pancreatic cancers implanted in the peritoneal cavity of immunocompromised mice.

Ejemplares similares